 |
Diseases |  |
Trials |
|
Trials |  |
News |  |
- | SHR-A2102 / Jiangsu Hengrui Pharma, Ariely (adebrelimab) / Jiangsu Hengrui Pharma
New P2 trial: An exploratory trial of SHR-A2102 in combination with Adebrelimab for the treatment of unresectable stage III non-small cell lung cancer (EUDRACT) - Apr 2, 2025
P2, N=20, Not yet recruiting, Sponsor: Shanghai Chest Hospital; Shanghai Chest Hospital
- ||||| SHR-A2102 / Jiangsu Hengrui Pharma
New P2 trial: A Trial of SHR-A2102 With Other Antitumor Therapies in Advanced Solid Tumors (clinicaltrials.gov) - Mar 26, 2025
P2, N=400, Not yet recruiting, Sponsor: Shanghai Hengrui Pharmaceutical Co., Ltd.
- || SHR-A2102 / Jiangsu Hengrui Pharma
Enrollment closed, Enrollment change: SHR-A2102-I-102: Phase I Study of SHR-A2102 in Patients With Advanced Solid Tumors (clinicaltrials.gov) - Mar 25, 2025
P1, N=395, Active, not recruiting, Sponsor: Shanghai Hengrui Pharmaceutical Co., Ltd.
Recruiting --> Active, not recruiting | N=200 --> 395
- |||||| SHR-A2102 / Jiangsu Hengrui Pharma
Enrollment open: A Phase III Study of SHR-A2102 Versus Investigator-selected Therapy in Advanced Urothelial Carcinoma (clinicaltrials.gov) - Mar 5, 2025
P3, N=402, Recruiting, Sponsor: Shanghai Hengrui Pharmaceutical Co., Ltd.
Recruiting --> Active, not recruiting | N=200 --> 395 Not yet recruiting --> Recruiting
- | SHR-A2102 / Jiangsu Hengrui Pharma, Ariely (adebrelimab) / Jiangsu Hengrui Pharma
New P2 trial: SHR-A2102 Combined with Adebrelimab As Neoadjuvant Therapy for Early Triple-Negative Breast Cancer (clinicaltrials.gov) - Feb 11, 2025
P2, N=52, Not yet recruiting, Sponsor: Henan Cancer Hospital
- SHR-A2102 / Jiangsu Hengrui Pharma
Nectin-4 targeted ADC, SHR-A2102, in patients with advanced or metastatic urothelial carcinoma: A phase 1 study. (Level 3, Ballroom) - Jan 7, 2025 - Abstract #ASCOGU2025ASCO_GU_563;
P1
SHR-A2102 showed promising anti-tumor activity in pts with advanced or metastatic urothelial carcinoma, even after ADC therapy, along with manageable safety profile. Efficacy summary.
- ||| SHR-A2102 / Jiangsu Hengrui Pharma
Enrollment open: SHR-A2102-201: A Trial of SHR-A2102 With or Without Antitumor Therapy in Advanced Solid Tumors (clinicaltrials.gov) - Jan 4, 2025
P1/2, N=80, Recruiting, Sponsor: Shanghai Hengrui Pharmaceutical Co., Ltd.
Efficacy summary. Not yet recruiting --> Recruiting
- |||||||||| SHR-A2102 / Jiangsu Hengrui Pharma
New P3 trial: A Phase III Study of SHR-A2102 Versus Investigator-selected Therapy in Advanced Urothelial Carcinoma (clinicaltrials.gov) - Dec 18, 2024
P3, N=402, Not yet recruiting, Sponsor: Shanghai Hengrui Pharmaceutical Co., Ltd.
- ||| SHR-A2102 / Jiangsu Hengrui Pharma
Enrollment open, Combination therapy, Metastases: A Trial of SHR-A2102 With Antitumor Therapy in Advanced Urothelial Carcinoma (clinicaltrials.gov) - Nov 18, 2024
P1/2, N=90, Recruiting, Sponsor: Shanghai Hengrui Pharmaceutical Co., Ltd.
Not yet recruiting --> Recruiting Not yet recruiting --> Recruiting
- ||| SHR-A2102 / Jiangsu Hengrui Pharma, Ariely (adebrelimab) / Jiangsu Hengrui Pharma, SHR-8068 / Jiangsu Hengrui Pharma
Enrollment open: A Study of SHR-A2102 in Combination With Adebrelimab and SHR-8068 in Subjects With Locally Advanced or Metastatic Non-Small Cell Lung Cancer (clinicaltrials.gov) - Nov 12, 2024
P1/2, N=124, Recruiting, Sponsor: Shanghai Hengrui Pharmaceutical Co., Ltd.
Not yet recruiting --> Recruiting Not yet recruiting --> Recruiting
- |||| SHR-A2102 / Jiangsu Hengrui Pharma
New P2 trial, Metastases: A Trial of SHR-A2102 for Treatment of Advanced Gynecological Malignancy (clinicaltrials.gov) - Oct 23, 2024
P2, N=100, Not yet recruiting, Sponsor: Shanghai Hengrui Pharmaceutical Co., Ltd.
- | New P2 trial: Platform Study of ADC Rechallenge in ADC-treated Metastatic Breast Cancer (clinicaltrials.gov) - Oct 17, 2024
P2, N=120, Recruiting, Sponsor: Fudan University
- |||| SHR-A2102 / Jiangsu Hengrui Pharma
New P1/2 trial, Combination therapy, Metastases: A Trial of SHR-A2102 With Antitumor Therapy in Advanced Urothelial Carcinoma (clinicaltrials.gov) - Oct 15, 2024
P1/2, N=90, Not yet recruiting, Sponsor: Shanghai Hengrui Pharmaceutical Co., Ltd.
- | Enrollment change: BCTOP-L-M05: SNF Platform Study of HR+/ HER2-advanced Breast Cancer (clinicaltrials.gov) - Oct 4, 2024
P2, N=620, Recruiting, Sponsor: Fudan University
Not yet recruiting --> Recruiting N=140 --> 620
- |||| SHR-A2102 / Jiangsu Hengrui Pharma, Ariely (adebrelimab) / Jiangsu Hengrui Pharma, SHR-8068 / Jiangsu Hengrui Pharma
New P1/2 trial, Combination therapy, Metastases: A Study of SHR-A2102 in Combination With Adebrelimab and SHR-8068 in Subjects With Locally Advanced or Metastatic Non-Small Cell Lung Cancer (clinicaltrials.gov) - Sep 20, 2024
P1/2, N=124, Not yet recruiting, Sponsor: Shanghai Hengrui Pharmaceutical Co., Ltd.
- |||| SHR-A2102 / Jiangsu Hengrui Pharma, Ariely (adebrelimab) / Jiangsu Hengrui Pharma
Enrollment open: A Trial of SHR-A2102 With Adebrelimab With or Without Other Antitumor Therapy in Advanced or Metastatic Non-small Cell Lung Cancer (clinicaltrials.gov) - Aug 15, 2024
P1/2, N=248, Recruiting, Sponsor: Shanghai Hengrui Pharmaceutical Co., Ltd.
N=140 --> 620 Not yet recruiting --> Recruiting
- |||| New P2 trial, Metastases: Exploratory Platform Research on Precision Therapy of Advanced Pancreatic Cancer (clinicaltrials.gov) - Aug 9, 2024
P2, N=120, Not yet recruiting, Sponsor: Fudan University
- ||||| SHR-A2102 / Jiangsu Hengrui Pharma, Ariely (adebrelimab) / Jiangsu Hengrui Pharma
New P1/2 trial: A Trial of SHR-A2102 With Adebrelimab With or Without Other Antitumor Therapy in Advanced or Metastatic Non-small Cell Lung Cancer (clinicaltrials.gov) - Jul 22, 2024
P1/2, N=248, Not yet recruiting, Sponsor: Shanghai Hengrui Pharmaceutical Co., Ltd.
- ||| SHR-A2102 / Jiangsu Hengrui Pharma, Ariely (adebrelimab) / Jiangsu Hengrui Pharma
Enrollment open: SHR-A2102-203: A Trial of SHR-A2102 With Adebrelimab With or Without Other Antitumor Therapy in Advanced or Metastatic Esophageal Cancer (clinicaltrials.gov) - Jul 9, 2024
P1/2, N=148, Recruiting, Sponsor: Shanghai Hengrui Pharmaceutical Co., Ltd.
Not yet recruiting --> Recruiting Not yet recruiting --> Recruiting
- |||| SHR-A2102 / Jiangsu Hengrui Pharma, Ariely (adebrelimab) / Jiangsu Hengrui Pharma
New P1/2 trial: SHR-A2102-203: A Trial of SHR-A2102 With Adebrelimab With or Without Other Antitumor Therapy in Advanced or Metastatic Esophageal Cancer (clinicaltrials.gov) - Jun 25, 2024
P1/2, N=148, Not yet recruiting, Sponsor: Shanghai Hengrui Pharmaceutical Co., Ltd.
- |||| SHR-A2102 / Jiangsu Hengrui Pharma
New P1/2 trial: SHR-A2102-201: A Trial of SHR-A2102 With or Without Antitumor Therapy in Advanced Solid Tumors (clinicaltrials.gov) - May 16, 2024
P1/2, N=80, Not yet recruiting, Sponsor: Shanghai Hengrui Pharmaceutical Co., Ltd.
- ||| SHR-A2102 / Jiangsu Hengrui Pharma
Enrollment open: SHR-A2102-I-102: Phase I Study of SHR-A2102 in Patients With Advanced Solid Tumors (clinicaltrials.gov) - May 31, 2023
P1, N=200, Recruiting, Sponsor: Shanghai Hengrui Pharmaceutical Co., Ltd.
Not yet recruiting --> Recruiting Not yet recruiting --> Recruiting
- ||| SHR-A2102 / Jiangsu Hengrui Pharma
Enrollment open, Metastases: A Phase 1 Study of SHR-A2102 in Subjects With Advanced Solid Tumors. (clinicaltrials.gov) - Mar 28, 2023
P1, N=252, Recruiting, Sponsor: Shanghai Hengrui Pharmaceutical Co., Ltd.
Not yet recruiting --> Recruiting Not yet recruiting --> Recruiting
- ||| SHR-A2102 / Jiangsu Hengrui Pharma
New P1 trial, Metastases: A Phase 1 Study of SHR-A2102 in Subjects With Advanced Solid Tumors. (clinicaltrials.gov) - Feb 21, 2023
P1, N=252, Not yet recruiting, Sponsor: Shanghai Hengrui Pharmaceutical Co., Ltd.
- ||| SHR-A2102 / Jiangsu Hengrui Pharma
New P1 trial: SHR-A2102-I-102: Phase I Study of SHR-A2102 in Patients With Advanced Solid Tumors (clinicaltrials.gov) - Jan 27, 2023
P1, N=200, Not yet recruiting, Sponsor: Shanghai Hengrui Pharmaceutical Co., Ltd.
- | Enrollment open: BCTOP-L-M05: SNF Platform Study of HR+/ HER2-advanced Breast Cancer (clinicaltrials.gov) - Jan 4, 2023
P2, N=140, Recruiting, Sponsor: Fudan University
Not yet recruiting --> Recruiting Not yet recruiting --> Recruiting
- | New P2 trial: BCTOP-L-M05: SNF Platform Study of HR+/ HER2-advanced Breast Cancer (clinicaltrials.gov) - Oct 26, 2022
P2, N=140, Not yet recruiting, Sponsor: Fudan University